Enzomenib
Based on 1 Customer Validation
Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.88%
- CAS No.: 2412555-70-3
- Formule: C33H43FN6O3
- Masse moléculaire:590.73
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Reprogramming Compound Library
HY-L039
-
Orally Active Compound Library
HY-L061
-
Anti-Blood Cancer Compound Library
HY-L079
-
Membrane Protein-targeted Compound Library
HY-L149
-
Highly Selective Inhibitors Library
HY-L158
-
Cytokine Inhibitors Library
HY-L161
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
Activité biologique
Specific MEN1 mutations confer resistance to Enzomenib (DSP-5336) in MOLM13 acute myeloid leukemia cells, resulting in reduced drug efficacy[1].
Enzomenib exhibits selective cell growth inhibitory activity against human acute leukemia cell lines harboring MLL rearrangement or NPM1 mutation[2].
Enzomenib selectively inhibits the growth of human leukemia cell lines with MLL rearrangement or NPM1 mutation[3].
Enzomenib downregulates the expression of leukemia genes MEIS1 and HOXA9, and upregulates the expression of terminal differentiation marker ITGAM in MV-4-11 cells[3].
Enzomenib potently inhibits colony formation and modulates the expression of HOXA9, MEIS1 and ITGAM in primary AML model samples positive for the MLL-AF6 fusion[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MV-4-11, MOLM-13, KOPN-8, and OCI-AML3 & human leukemia cell lines
-
Concentration:IC50
-
Incubation Time:/
-
Result:Inhibited the growth of MLL-rearranged or NPM1-mutated human leukemia cell lines with IC50 values of 10 nM (MV-4-11), 15 nM (MOLM-13), 31 nM (KOPN-8), and 15 nM (OCI-AML3).
Did not affect the cell growth of human leukemia cell lines such as HL-60, MOLT-4, and Reh, with IC50s>10 μM.
Enzomenib (DSP-5336) (200 mg/kg; p.o.; once daily) significantly prolongs survival in syngeneic MLL-ENL or MLL-AF10 AML mice, outperforming standard chemotherapy[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Acute myeloid leukemia mice model[3]
-
Dosage:200 mg/kg
-
Administration:p.o.; once daily
-
Result:Induced significant prolongation of survival compared to both vehicle control and standard chemotherapy (cytarabine+daunorubicin) groups.
Chemical Information
-
CAS No. 2412555-70-3
-
Appearance Solid
-
Masse moléculaire 590.73
-
Formule C33H43FN6O3
-
Color White to off-white
-
SMILES
O=C([C@@H](N[C@]1([H])C2)[C@@](CC1)([H])C2=C)N3CCC4(CC3)CN(C5=NC=NC=C5OC(C=CC(F)=C6)=C6C(N(C(C)C)C(C)C)=O)C4
-
Synonyms
DSP-5336
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 66.67 mg/mL (112.86 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (8.46 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6928 mL | 8.4641 mL | 16.9282 mL | 42.3205 mL |
| 5 mM | 0.3386 mL | 1.6928 mL | 3.3856 mL | 8.4641 mL | |
| 10 mM | 0.1693 mL | 0.8464 mL | 1.6928 mL | 4.2321 mL | |
| 15 mM | 0.1129 mL | 0.5643 mL | 1.1285 mL | 2.8214 mL | |
| 20 mM | 0.0846 mL | 0.4232 mL | 0.8464 mL | 2.1160 mL | |
| 25 mM | 0.0677 mL | 0.3386 mL | 0.6771 mL | 1.6928 mL | |
| 30 mM | 0.0564 mL | 0.2821 mL | 0.5643 mL | 1.4107 mL | |
| 40 mM | 0.0423 mL | 0.2116 mL | 0.4232 mL | 1.0580 mL | |
| 50 mM | 0.0339 mL | 0.1693 mL | 0.3386 mL | 0.8464 mL | |
| 60 mM | 0.0282 mL | 0.1411 mL | 0.2821 mL | 0.7053 mL | |
| 80 mM | 0.0212 mL | 0.1058 mL | 0.2116 mL | 0.5290 mL | |
| 100 mM | 0.0169 mL | 0.0846 mL | 0.1693 mL | 0.4232 mL |
Powered by Bioz